Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vorolanib + toripalimab first-line treatment for advanced or unresectable clear cell renal cell carcinoma
ChiCTR2400093213Phase 2Not yet recruiting
- Sponsor
- Yunnan Cancer Hospital
- Start
- Nov 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vorolanib and toripalimab in clear cell renal cell carcinoma (ccRCC), sponsored by Yunnan Cancer Hospital. Primary endpoint: Progression-free survival (IRC). Planned start Nov 2024; status: not yet recruiting.
02
Drugs
vorolanibtoripalimab
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on ChiCTR2400093213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400093213.